이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

원격 모니터링 플랫폼 "CUREETY TECHCARE"와 1차 치료를 시작하는 mTBNC 환자를 위한 표준 치료 비교 (ALTERNATIVE)

2026년 9월 24일 업데이트: UNICANCER

1차 전신 치료를 시작하는 삼중 음성 전이성 유방암 환자의 디지털 원격 모니터링 플랫폼 "CUREETY TECHCARE"를 일반적인 표준 치료와 비교하는 무작위 3상 연구

The goal of this clinical trial is to assess whether adding telemonitoring (the digital telemonitoring platform "CUREETY TECHCARE"), to standard care, will benefit patients with previously untreated metastatic triple-negative breast cancer starting first-line cancer therapy.

The main questions it aims to answer are:

  • Is patient quality of life improved by using the telemonitoring platform?
  • Are patients hospitalized less frequently when using the telemonitoring platform?
  • Is the patient overall survival improved by telemonitoring ?

Researchers will compare data from patients using telemonitoring while receiving standard care with data from patients receiving only standard care.

Participants using telemonitoring will answer questions about their symptoms on the platform. The platform will analyze these symptoms, assess the patient's general condition and provide advice accordingly. Medical staff will also access the platform to monitor the patient's general condition and contact them if necessary.

연구 개요

상태

종료됨

정황

개입 / 치료

연구 유형

중재적

등록 (실제)

31

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Arras, 프랑스
        • Institut de Cancérologie des Hauts-de-France (ICHF)
      • Auxerre, 프랑스
        • Centre Hospitalier d'Auxerre
      • Avignon, 프랑스
        • Sainte Catherine - Institut du Cancer Avignon Provence
      • Bayeux, 프랑스
        • CH Aunay-Bayeux
      • Beauvais, 프랑스
        • Centre Hospitalier Simone Veil de Beauvais
      • Beuvry, 프랑스
        • ICHF - Centre Pierre Curie
      • Blois, 프랑스
        • Hôpital Simone Veil de Blois
      • Bordeaux, 프랑스
        • Polyclinique bordeaux nord
      • Bourg-en-Bresse, 프랑스
        • Centre Hospitalier Fleyriat
      • Caen, 프랑스
        • Centre de Cancérologie Privé de Caen Maurice Tubiana
      • Caen, 프랑스
        • Centre Francois Baclesse
      • Carcassonne, 프랑스
        • Centre hospitalier de Carcasonne
      • Chambray-lès-Tours, 프랑스
        • Recherche Oncologie Clinqiue 37 (ROC 37)
      • Cholet, 프랑스
        • CH de Cholet
      • Colmar, 프랑스
        • CH Colmar
      • Creil, 프랑스
        • Groupe Hospitalier Public du Sud de l'Oise (GHPSO)
      • Dijon, 프랑스
        • Centre Georges François Leclerc
      • Dunkirk, 프랑스
        • Institut Andrée Dutreix
      • Fréjus, 프랑스
        • Centre Hospitalier Intercommunal de Fréjus Saint Raphael
      • Grenoble, 프랑스
        • Groupe Hospitalier Mutualiste de Grenoble
      • La Rochelle, 프랑스
        • Groupe Hospitalier de La Rochelle-Ré-Aunis
      • La Réunion, 프랑스
        • CHU de la réunion
      • La Réunion, 프랑스
        • Clinique Sainte Clotilde
      • La Tronche, 프랑스
        • CHU Grenoble Alpes
      • Le Coudray, 프랑스
        • Centre Hospitalier Louis Pasteur
      • Le Mans, 프랑스
        • Centre Hospitalier Le Mans
      • Le Puy-en-Velay, 프랑스
        • Centre Hospitalier Emile Roux
      • Lorient, 프랑스
        • GHBS Lorient
      • Lyon, 프랑스
        • Clinique de la Sauvegarde
      • Lyon, 프랑스
        • Centre Leon Berard
      • Lyon, 프랑스
        • Hôpital Privé Jean Mermoz
      • Marseille, 프랑스
        • Institut Paoli Calmettes
      • Mont-de-Marsan, 프랑스
        • CHI de Mont-de-Marsan et du Pays des Sources
      • Montpellier, 프랑스
        • Centre de Cancérologie du Grand Montpellier
      • Nantes, 프랑스
        • Hôpital Privé du Confluent
      • Neuilly-sur-Seine, 프랑스
        • Clinique Ambroise-Pare Hartmann
      • Neuilly-sur-Seine, 프랑스
        • Hôpital Américain de PARIS
      • Nîmes, 프랑스
        • CHU de Nimes
      • Orléans, 프랑스
        • CHR Orleans
      • Osny, 프랑스
        • CHP Sainte-Marie
      • Paris, 프랑스
        • Diaconesses Croix Saint-Simon Hospital Complex
      • Pau, 프랑스
        • Centre hospitalier de Pau
      • Plérin, 프랑스
        • CARIO - Hopital Privé des Cotes d'Armor
      • Poitiers, 프랑스
        • CHU de Poitiers
      • Reims, 프랑스
        • Institut Godinot
      • Rouen, 프랑스
        • Clinique Mathilde - Les Hôpitaux Privés Rouennais
      • Saint-Etienne, 프랑스
        • CHU de Saint-Etienne
      • Saint-Mandé, 프랑스
        • Hia Begin
      • Tours, 프랑스
        • CHU de Tours
      • Vandœuvre-lès-Nancy, 프랑스
        • Institut de Cancérologie de Lorraine
      • Épagny, 프랑스
        • CH Annecy Genevois

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Signed a written informed consent form prior to participate in the study. Note: In case of physical incapacitation, a trusted representative of their choice, which is not the Investigator or sponsor, can sign on the behalf of the patients
  • Patients ≥18 years of age.
  • Patient with histologically documented metastatic triple negative breast cancer (ER (Oestrogen receptor) and PR (Progesterone receptor) <10%, Her2 negative status).
  • Life expectancy > 6 months as per investigator estimate.
  • Patient initiating a marketed authorized first-line systemic treatment in the metastatic setting.
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2.
  • Patient having completed the EORTC QLQ-C30 and EORTC QLQ-BR45 at baseline (response to questions 29 and 30 of EORTC QLQ-C30 at baseline are mandatory)
  • Affiliated to the social security system or equivalent health insurance.
  • Patient able and willing to complete web-based self-reported questionnaires, from initiation of first-line treatment and for the duration of the study (over multiple treatment lines)
  • Patient has access to a computer, tablet, or smartphone connected to the Internet.

Exclusion Criteria:

  • Participation in another clinical trial using telemonitoring.
  • Physical or psychological incapacity of the patient to use the digital telemonitoring Cureety Techcare, according to the investigator's discretion.
  • Patient deprived of their liberty or under protective custody or guardianship.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 지지 요법
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
간섭 없음: 표준 치료 그룹
실험적: Telemonitoring group

Standard of care with digital telemonitoring "Cureety TechCare". The telemonitoring will comprise weekly adverse event (AE) evaluations and their analyses by the "Cureety TechCare".

Each week, patients complete a questionnaire via the Cureety platform, specifically designed for the drug class or specific treatment being administered. Based on their responses, the Cureety TechCare algorithm classifies patients into one of four risk categories: "correct" (green), "compromised" (yellow), "state to be monitored" (orange), or "critical state" (red). (Note: the color code is not visible to the patient).

The medical team uses the dashboard for daily patient monitoring and manages alerts related to the "clinical classification" of the patient's condition. The physician in charge of telemonitoring interprets the data, adjusts the treatment as needed, and provides supportive care during standard care consultations. Patients are also notified of alerts with tailored messages guiding them on the actions to take according to the category determined by the device.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Time to definitive Health-Related Quality of life score Deterioration
기간: At baseline then every 3 months, up to 24 months

The time to definitive Health-Related Quality of life score Deterioration is the length of time from randomization to the first deterioration of ≥ 10 points out of 100 or ≥2 points out of 14 in the global health status (GHS) score (items 29 and 30 of the QLQ-C30) compared with the baseline, assuming no improvement of at least 2 points in the GHS score compared with the baseline has occurred.

The responses to the items 29-30 of the QLQ-C30 will be scored using the QLQ scoring manual. These 2 items have possible values ranging from 1 (very bad) to 7 (excellent) corresponding to a sum from 2 to 14 points. After conversion to percentages, the GHS will range from 0% to 100%. The higher the value, the better the quality of life.

At baseline then every 3 months, up to 24 months
Hospitalization-free survival
기간: From randomization to death from any cause, up to 24 months

Hospitalization-free survival is the length of time from randomization during which patients enrolled in the study are not hospitalized and remain alive.

From randomization to death from any cause, up to 24 months
Overall survival
기간: From randomization to death from any cause, up to 24 months after last inclusion

overall survival is the length of time from randomization during which patients enrolled in the study remain alive.

From randomization to death from any cause, up to 24 months after last inclusion

2차 결과 측정

결과 측정
측정값 설명
기간
Time-to-treatment failure
기간: From randomization to treatment discontinuation, up to 24 months

Time-to-treatment failure is the time interval (in months) between the initiation of first-line chemotherapy and its premature discontinuation, irrespective of the reason for discontinuation.

From randomization to treatment discontinuation, up to 24 months
Toxicity-free survival
기간: From randomization until the first event, up to 24 months

The National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5) is widely accepted in the oncology research community as the leading rating scale for adverse events. This scale, divided into five grades (1 = "mild," 2 = "moderate," 3 = "severe," 4 = "life-threatening," and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders. Toxicity-free survival is defined as the time from randomization to the first event among a grade 3-4 non-hematological adverse event (graded using CTCAE version 5.0), a hospitalization for safety reasons, or death from any cause, whichever occurs first.

From randomization until the first event, up to 24 months
Time to clinical deterioration
기간: From randomization, to the date of the first clinical deterioration, up to 24 months

-Time to clinical deterioration is defined by the time between randomization and deterioration of patient's level of functioning determined by the Eastern Cooperative Oncology Group (ECOG) performance status scale. The ECOG, widely accepted in the community of oncology research to assess how the disease affects the daily living abilities of the patient, is composed of 5 levels from grade 0 (fully active, able to carry on all pre-disease performance without restriction) to grade 5 (dead).

From randomization, to the date of the first clinical deterioration, up to 24 months
Number of treatment lines
기간: Throughout study completion, up to 24 months

Number of successive treatment lines offered to the patient from randomization to the end of the study.

Throughout study completion, up to 24 months
Incidence of Adverse Events
기간: Throughout study completion, up to 24 months

The National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5) is widely accepted in the community of oncology research as the leading rating scale for adverse events. This scale, divided into 5 grades (1 = "mild", 2 = "moderate", 3 = "severe", 4 = "life-threatening", and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders.

Throughout study completion, up to 24 months
Quality of life questionnaire - Core 30 (QLQ-C30)
기간: At baseline then every 3 weeks, up to 24 months

Developed by the EORTC, this self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials.

The questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease.

All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

At baseline then every 3 weeks, up to 24 months
Quality of Life Questionnaire - Breast cancer module (QLQ-BR45)
기간: At baseline then every 3 weeks, up to 24 months

This EORTC breast cancer specific questionnaire is intended to supplement the QLQ-C30.

The QLQ-BR45 incorporates nine multi-item scales to assess body image, sexual functioning, breast satisfaction, systemic therapy side effects, arm symptoms, breast symptoms, endocrine therapy symptoms, skin mucosis symptoms, endocrine sexual symptoms. In addition, single items assess sexual enjoyment, future perspective and being upset by hair loss. All items are rated on a four-point Likert-type scale (1 = "not at all", 2 = "a little", 3 = "quite a bit", and 4 = "very much"), and are linearly transformed to a 0-100 scale. Higher scores indicate more severe symptoms or problems for all items.

At baseline then every 3 weeks, up to 24 months
Treatment compliance and extent of exposure
기간: Throughout study completion, up to 24 months

The treatment compliance and extent of exposure will be assess using dose intensity, treatment delays and dose reductions.

Throughout study completion, up to 24 months
Compliance with the use of Cureety digital telemonitoring
기간: Throughout study completion, up to 24 months

Compliance is measured by the frequency of patient responses to the Cureety telemonitoring questionnaires.

Throughout study completion, up to 24 months
Satisfaction with Cureety telemonitoring
기간: 3 months after randomisation for the patients and 1 year after the site activation for medical team

Satisfaction with Cureety telemonitoring is measured by the percentage of participants (patients and medical team [including nurse, clinical research associate, and investigators]) satisfied by the regular usage of the Cureety telemonitoring tool.

3 months after randomisation for the patients and 1 year after the site activation for medical team
Patient's global satisfaction with care using the data of the EORTC OUT-PATSAT-35
기간: 6 months after randomisation

The OUT-PATSAT35 is a 35-item satisfaction with care questionnaire measuring cancer outpatients' perception of hospital doctors and nurses, as well as aspects of care organisation and services. Each item is rated from 1 to 5 (bad to excellent).

6 months after randomisation
Socio-economic impact of digital telemonitoring
기간: Throughout study completion, up to 24 months after randomization

Socio-economic impact of digital telemonitoring will be assessed using the number of days of hospitalization and the number of unscheduled hospitalizations and emergency consultations

Throughout study completion, up to 24 months after randomization

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 수석 연구원: Jérôme MARTIN-BABAU, MD, Armorican Centre for Radiotherapy, Medical Imaging and Oncology, CARIO, Plérin
  • 수석 연구원: Florence JOLY, MD, François Baclesse Center, Caen
  • 수석 연구원: Frédéric FITENI, MD, University hospital of Nîmes

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 7월 25일

기본 완료 (실제)

2025년 12월 1일

연구 완료 (실제)

2025년 12월 12일

연구 등록 날짜

최초 제출

2024년 7월 10일

QC 기준을 충족하는 최초 제출

2024년 7월 10일

처음 게시됨 (실제)

2024년 7월 17일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 29일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 24일

마지막으로 확인됨

2025년 8월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • UC-BCG-2309
  • IDRCB NUMBER: 2023-A02477-38 (기타 식별자: CPP Sud-Méditerranée III)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

Individual Participant Data will not be shared at an individual level. Those data will be part of the study database including all enrolled patients.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .